First-Pass Metabolism

The anatomy that makes it happen

Take a moment to appreciate how strange the blood supply of the gut is. Mesenteric arteries deliver oxygenated blood to the stomach, small intestine, and colon — that part is ordinary. But the venous drainage doesn't run straight back to the heart. Instead, the superior mesenteric vein, inferior mesenteric vein, and splenic vein converge into the portal vein, which carries every absorbed nutrient and every absorbed drug directly into the liver.

Inside the liver, portal blood mixes with arterial blood from the hepatic artery in the sinusoids — the liver's specialized capillaries — before draining into central veins, the hepatic vein, and finally the inferior vena cava on its way back to the heart. The result: every orally absorbed molecule must run a gauntlet of hepatocytes before reaching the systemic circulation.

About 1,000 mL/min of portal blood flow reaches the liver — roughly 75% of its total perfusion. Hepatocytes line the sinusoids and express the CYP enzymes, glucuronidases, sulfotransferases, and transporters that constitute phase I and phase II metabolism. A drug that is a good substrate for those enzymes can be cleared aggressively on the first pass.

How first-pass loss happens

There are three sequential places where an oral drug can be destroyed or excluded before it ever reaches the systemic blood:

1. Gut lumen. Stomach acid (penicillin G, insulin), gut bacteria (digoxin, levodopa partially), pancreatic enzymes can break down or modify the drug before absorption.
2. Intestinal wall (enterocyte). The apical membrane expresses P-glycoprotein and BCRP transporters that pump substrates back into the lumen. Inside the enterocyte, CYP3A4 is highly expressed — sometimes contributing as much first-pass extraction as the liver itself. For cyclosporine, midazolam, and felodipine, gut wall metabolism is the dominant source of first-pass loss.
3. Liver. Hepatocytes take up the drug via OATP1B1, OATP1B3, OCT1, and other transporters, then metabolize it with the full CYP and phase II battery. High-extraction drugs have hepatic extraction ratios (E) above 0.7.

The "well-stirred" model of hepatic clearance gives a clean intuition: F = 1 − E, where E is the extraction ratio. A drug with E = 0.75 (the morphine case) has oral bioavailability of 25%. A drug with E = 0.1 (low-extraction, like warfarin) has F near 90%.

The real numbers

• Morphine. Oral F ≈ 25%; IV F = 100%. The clinical conversion ratio is roughly 1 mg IV ↔ 3 mg PO morphine for opioid-naive patients. Sublingual morphine is poorly absorbed; rectal is ~30%.
• Nitroglycerin. Oral F < 1% — essentially destroyed. Sublingual ~40%. IV 100%. This is why sublingual is the standard route for acute anginal pain; the molecule reaches coronary circulation within 1–3 minutes and aborts ischemia.
• Propranolol. Oral F ≈ 25%; the IV-to-PO ratio is roughly 1:4. In cirrhosis, F can rise to ~75% because of portosystemic shunting and reduced hepatocyte mass.
• Lidocaine. Oral F ≈ 30%, but first-pass produces a toxic metabolite (MEGX). Lidocaine is therefore never given orally for systemic effect — it is given IV (cardiac arrhythmia) or topical.
• Buprenorphine. Oral F < 10% because of extensive CYP3A4 metabolism. Sublingual film/tablet F ≈ 30%. Subcutaneous depot F closer to 100% in steady state. The drug's clinical use is built around its sublingual route.
• Naloxone. Oral F < 2%. Intranasal F ~50%. IV/IM 100%. The intranasal Narcan spray (the lay-rescuer overdose treatment that has saved tens of thousands of lives in the US opioid epidemic) only became possible once formulations achieved adequate intranasal bioavailability.
• Verapamil. Oral F ≈ 22% via CYP3A4 metabolism. Grapefruit juice raises F substantially by inhibiting intestinal CYP3A4.
• Levodopa. Oral F ≈ 30% on its own. Combined with carbidopa (which blocks peripheral DOPA decarboxylase but cannot cross the blood-brain barrier), more L-dopa reaches the brain — though carbidopa addresses peripheral metabolism, not strictly first-pass.

Why we have so many routes of administration

Every alternate route in pharmacology exists, in part, to dodge first-pass metabolism. The major bypasses:

• Intravenous (IV). Direct injection into the systemic vein. F = 1.0 by definition. Fast onset, full bioavailability, full liability if dose is wrong.
• Intramuscular (IM), subcutaneous (SC). Drug absorbs from the injection site into local veins that drain to the heart. F typically 80–100% for small molecules; slower onset than IV.
• Sublingual / buccal. The veins under the tongue and inside the cheek drain to the superior vena cava and the heart — bypassing the portal vein. Nitroglycerin, sublingual buprenorphine, sublingual fentanyl, sublingual sumatriptan all exploit this.
• Transdermal. Drug crosses the skin and enters local cutaneous veins. Fentanyl patches, nicotine patches, nitroglycerin patches, scopolamine patches.
• Inhaled. Drug deposits in alveoli, crosses the alveolar epithelium, enters pulmonary veins, and reaches the left heart in one pass. Inhaled albuterol, fluticasone, anesthetic gases (sevoflurane, desflurane).
• Nasal. Mucosa drains to systemic circulation. Intranasal naloxone (Narcan), sumatriptan, desmopressin.
• Rectal. Anatomically complex. The lower rectum drains around the liver (via the inferior and middle rectal veins to the inferior vena cava). The upper rectum drains into the portal system. Rectal absorption is therefore partly first-pass — variable and dependent on where the drug deposits.

Clinical implications

• Opioid conversion errors are deadly. An IV morphine dose given orally is sub-therapeutic; an oral dose given IV can stop breathing. The 1:3 PO:IV conversion ratio for morphine reflects 25% oral bioavailability. Hospital errors that swap routes without recalculating dose are a recurring source of opioid-related harm.
• Cirrhosis cracks every assumption. Portosystemic shunting and reduced hepatocyte mass raise F for high-extraction drugs dramatically. Standard outpatient propranolol doses can sedate or hypotensive a cirrhotic patient. Dose reductions of 50–75% are routine for high-extraction drugs in Child-Pugh B/C cirrhosis.
• Drug-drug interactions amplify the effect. Grapefruit juice inhibits intestinal CYP3A4, raising felodipine F from 15% to 50%+. Strong CYP3A4 inhibitors like ritonavir, ketoconazole, and clarithromycin can multiply F for drugs that depend on first-pass metabolism for safety.
• Special populations. Neonates and infants have immature CYP expression; they can have higher F for some drugs and need dose adjustment. Elderly patients have reduced hepatic blood flow, sometimes increasing F for high-extraction drugs.
• Drug development decisions. When a drug has poor oral F, formulators look for prodrugs (a more permeable, more stable form that is converted to active drug after absorption), permeation enhancers, P-gp inhibitors, lipid-based formulations (self-emulsifying drug delivery systems, SEDDS), or alternate routes.

A history note

The conceptual framework is mostly the work of the 1960s and 1970s. Leslie Benet at UCSF and others formalized the well-stirred and parallel-tube models of hepatic clearance, deriving the now-canonical equation that links F to extraction ratio and hepatic blood flow. Malcolm Rowland's pharmacokinetics textbook (first edition 1980) made first-pass metabolism standard pharmacology curriculum.

Sublingual nitroglycerin is much older — William Murrell first reported its use for angina in The Lancet in 1879, decades before anyone understood why it worked sublingually but not orally. The dose-route relationship was empirical for a century before the underlying anatomy became clinically actionable.

The modern era of route engineering — buprenorphine sublingual films, intranasal naloxone, transdermal fentanyl, inhaled insulin (briefly) — represents direct application of first-pass theory. A drug with poor oral bioavailability is no longer abandoned; it is reformulated for a route that fits.

Common misconceptions

• "Oral and IV doses are the same." Not for most drugs. The PO:IV ratio is set by F. Treating them as interchangeable causes overdose or under-treatment.
• "Sublingual is just absorption through the tongue." Anatomically, it's vein routing. The drug must reach a vein that drains around the portal system — the floor of the mouth does, the lower esophagus does not.
• "Bioavailability of 100% means the drug is highly effective." F describes how much reaches the blood unchanged — it says nothing about potency, efficacy, or therapeutic effect. A drug with F = 100% might still be useless if it has no target activity.
• "First-pass and metabolism are the same thing." First-pass is metabolism at a specific anatomical location and time — gut wall + liver, before systemic circulation. After steady state, drugs continue to be metabolized in the liver, but the first-pass term refers specifically to the initial transit.
• "Crushing an extended-release oral tablet is fine because it's the same drug." It can be lethal. Bypassing the extended-release matrix dumps the entire dose into the gut at once, often saturating first-pass metabolism and pushing systemic levels into toxic range. Crushed OxyContin caused exactly this problem.

Drugs with prominent first-pass metabolism

Drug	Oral F	IV F	Alternate route F	Why first-pass matters
Morphine	~25%	100%	Rectal ~30%, SL ~20%	1:3 PO:IV conversion; route swap risk
Nitroglycerin	<1%	100%	Sublingual ~40%, transdermal ~70%	Only the bypass routes are useful
Propranolol	~25%	100%	—	Rises to ~75% in cirrhosis
Lidocaine	~30%	100%	Topical (local)	Toxic first-pass metabolite (MEGX)
Buprenorphine	<10%	100%	Sublingual ~30%	Drives sublingual formulation choice
Naloxone	<2%	100%	Intranasal ~50%, IM 100%	Lay-rescuer route engineering
Verapamil	~22%	100%	—	Grapefruit juice raises F substantially
Midazolam	~30%	100%	Intranasal ~50%, IM ~90%	Probe drug for CYP3A4 activity